Transdermal Microneedle Patch Systems for Controlled Vaccine Delivery: Design Principles, Fabrication Technologies, Immunological Mechanisms, and Clinical Translation in Next-Generation Patient-Friendly Immunization

Dr. Michael Andrew Henderson
PhD, Center for Nanomedicine and Drug Delivery, University of North Carolina at Chapel Hill, USA

* Corresponding Author: **Dr. Michael Andrew Henderson**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 04
July- August 2024
Received: 08-05-2024
Accepted: 10-06-2024
Published: 12-07-2024
Page No: 37-44

Abstract
Transdermal microneedle patches represent a transformative advancement in vaccine delivery technology, offering painless, minimally invasive immunization through controlled antigen administration into skin layers enriched with antigen-presenting cells. These micron-scale devices circumvent limitations of conventional needle-syringe vaccination, including cold-chain dependence, needle-phobia, sharps disposal hazards, and requirement for trained healthcare personnel. This review comprehensively examines the design principles, fabrication methodologies, and immunological mechanisms underlying microneedle-based vaccine delivery systems. Various microneedle architectures are analyzed, including solid, coated, dissolving, hollow, and hybrid configurations, each offering distinct advantages for antigen stability, release kinetics, and immunogenicity enhancement. Emphasis is placed on materials engineering, manufacturing scalability, dose precision, and immune activation pathways mediated by Langerhans cells and dermal dendritic cells in skin immunization. Clinical applications spanning viral, bacterial, and subunit vaccines demonstrate comparable or superior immunological responses relative to intramuscular administration, with particular relevance for pandemic preparedness, mass immunization campaigns, and vulnerable populations. Despite promising preclinical and clinical data, challenges persist regarding manufacturing standardization, regulatory frameworks, long-term stability, and global deployment logistics. Future innovations integrating adjuvant incorporation, thermostable formulations, and multi-antigen delivery promise to establish microneedle patches as mainstream vaccination platforms, advancing patient compliance, healthcare accessibility, and immunization coverage worldwide.

DOI:

Keywords: Transdermal Vaccine Delivery, Microneedle Patches, Dissolving Microneedles, Skin Immunization, Needle-Free Vaccination, Controlled Antigen Release

1. Introduction

1.1. Evolution of Transdermal Vaccine Delivery

Conventional vaccine administration via intramuscular or subcutaneous injection, while effective, presents substantial practical limitations including needle-phobia affecting 20-50% of adults and children, stringent cold-chain requirements, biohazardous sharps waste, and dependence on trained healthcare workers[1,2]. Transdermal microneedle patches have emerged as innovative alternatives, leveraging microfabrication technologies to create arrays of micron-scale projections that penetrate the stratum corneum and deliver antigens to immunologically active dermal and epidermal layers without stimulating pain receptors located deeper in tissue[3,4].

1.2. Immunological Rationale for Skin-Based Vaccination
The skin harbors dense populations of professional antigen-presenting cells, particularly Langerhans cells in the epidermis and dermal dendritic cells, constituting a highly immunocompetent microenvironment [5]. Comparative studies demonstrate that equivalent or lower antigen doses delivered transdermally can elicit immune responses superior to intramuscular administration due to efficient antigen capture, processing, and presentation by skin-resident immune cells [6, 7]. This dose-sparing potential holds significant implications for vaccine accessibility and pandemic response strategies.

1.3. Scope and Objectives
This review provides comprehensive analysis of transdermal microneedle patch technologies for vaccine delivery, encompassing design architectures, fabrication methodologies, mechanisms of skin penetration and antigen release, immunological activation pathways, clinical applications across vaccine types, and translational challenges. Emphasis is placed on pharmaceutical engineering aspects, formulation strategies, and clinical evidence supporting microneedle-based immunization platforms.

2. Microneedle Patch Technologies for Vaccine Delivery
2.1. Solid and Coated Microneedles
Solid microneedles fabricated from biocompatible materials including silicon, metals, or polymers create transient microchannels through the stratum corneum, facilitating subsequent vaccine solution application [8]. However, the two-step administration process and potential antigen degradation limit clinical utility. Coated microneedles address these limitations by incorporating vaccine formulations onto needle surfaces using dip-coating, spray-coating, or electrospray techniques [9, 10]. Metal microneedles coated with inactivated influenza virus demonstrate rapid dissolution upon skin insertion, delivering precise antigen doses within minutes while maintaining structural integrity for removal [11].
Critical considerations for coated microneedles include coating uniformity, antigen stability during drying processes, loading capacity constraints (typically 0.1-1.0 µg per needle), and potential immunogenicity variations from incomplete dissolution[12]. Optimization strategies employ stabilizing excipients such as trehalose, polyvinylpyrrolidone, and carboxymethylcellulose to preserve antigen conformational integrity during fabrication and storage [13].

2.2. Dissolving and Biodegradable Microneedles
Dissolving microneedles, fabricated entirely from water-soluble or biodegradable polymers encapsulating vaccine antigens, represent the most clinically advanced microneedle platform [14]. Upon skin insertion, these needles dissolve completely within minutes to hours, releasing antigens into dermal tissues while leaving no sharps waste [15]. Commonly employed materials include polyvinylpyrrolidone, polyvinyl alcohol, carboxymethylcellulose, hyaluronic acid, and silk fibroin, selected based on biocompatibility, mechanical strength, dissolution kinetics, and antigen compatibility [16, 17].
Micromolding and microfabrication techniques enable precise control over needle geometry, antigen distribution, and dissolution profiles [18]. Vaccine antigens can be uniformly distributed throughout the needle matrix or concentrated in specific regions (tip-loading) to optimize release kinetics and dose delivery [19]. Biodegradable microneedles utilizing polylactic acid, polylactic-co-glycolic acid, or polycaprolactone provide sustained antigen release over extended periods, potentially enabling single-administration vaccination with prolonged immune stimulation [20, 21].

2.3. Hollow and Hybrid Microneedle Systems
Hollow microneedles function as miniaturized hypodermic needles, enabling liquid vaccine formulation delivery into dermal or intradermal spaces[22]. These systems accommodate larger vaccine volumes and maintain cold-chain-dependent formulations but require integrated fluid delivery mechanisms and seal maintenance to prevent backflow[23]. Applications include jet-injector-based systems and microinfusion devices for continuous or pulsatile antigen delivery.
Hybrid microneedle designs integrate multiple functionalities, such as biodegradable needle tips combined with non-dissolving backing layers for controlled insertion depth and mechanical support[24]. Separable microneedles featuring detachable tips that remain embedded in skin after backing removal enable extended antigen release without patch retention [25].

3. Mechanisms of Transdermal Vaccine Delivery
3.1. Skin Penetration and Antigen Deposition
Successful vaccine delivery requires microneedle penetration through the 10-20 µm stratum corneum into viable epidermis (50-100 µm depth) or superficial dermis (100-500 µm depth) without reaching pain-sensitive nerve endings located deeper than 1000 µm[26]. Needle geometry parameters including height (250-1500 µm), base width (50-300 µm), tip radius (1-10 µm), and inter-needle spacing directly influence penetration efficiency, determined by applied force, skin elasticity, and needle mechanical strength [27, 28].
Optimization studies establish that conical or pyramidal needle geometries with aspect ratios (height:base width) of 2:1 to 4:1 achieve reliable stratum corneum penetration with application forces of 5-30 N per array, well within painless pressure thresholds [29]. Insertion depths are verified using histological analysis, optical coherence tomography, or transepidermal water loss measurements confirming microstructure creation [30].

3.2. Controlled and Sustained Antigen Release
Antigen release kinetics from microneedle matrices depend on material composition, polymer molecular weight, crosslinking density, antigen-polymer interactions, and local tissue hydration [31]. Dissolving microneedles fabricated from rapidly soluble polymers release antigens within 5-30 minutes, generating acute immune stimulation comparable to conventional injection[32]. Conversely, slowly biodegrading polymers enable sustained antigen presentation over days to weeks, potentially eliminating booster dose requirements through prolonged immune activation [33].
Formulation strategies modulating release profiles include layered microneedle architectures with distinct polymer compositions in tips versus bases, co-encapsulation of

antigens with adjuvants for synchronized delivery, and pH-responsive or enzyme-degradable polymers responding to local tissue microenvironments [34, 35]. Sustained-release formulations demonstrate enhanced germinal center formation, prolonged antibody production, and improved immunological memory compared to bolus administration[36].

3.3. Immune Activation via Skin-Resident Immune Cells

Transdermal vaccine delivery capitalizes on the skin's specialized immune architecture, particularly the dense network of Langerhans cells (200-1000 cells/mm²) in the epidermis and dermal dendritic cells capable of efficient antigen capture, processing, and presentation to T cells in draining lymph nodes [37, 38]. Comparative immunological studies demonstrate that intradermal vaccination generates stronger cellular immune responses, broader antibody repertoires, and more durable immunological memory than intramuscular routes, attributed to superior dendritic cell activation and migration[39,40].

The mild inflammatory response induced by microneedle insertion may provide adjuvant effects through damage-associated molecular pattern release, complement activation, and cytokine production, enhancing antigen immunogenicity without exogenous adjuvant addition [41]. Toll-like receptor agonists, particulate adjuvants, or immunostimulatory polymers can be co-formulated with antigens in microneedle matrices to further amplify immune responses [42, 43].

4. Therapeutic and Preventive Applications

4.1. Viral and Bacterial Vaccines

Microneedle-delivered influenza vaccines represent the most extensively studied application, with multiple clinical trials demonstrating non-inferior immunogenicity compared to intramuscular injection [44]. Dissolving microneedle patches containing inactivated influenza virus elicit seroprotective antibody titers in over 90% of recipients, with improved thermostability enabling storage at 25°C for 12 months without potency loss[45,46]. Phase III trials of influenza microneedle patches have advanced toward regulatory approval, representing a landmark achievement for transdermal vaccine technology [47].

Additional viral vaccines successfully delivered via microneedles include measles, rubella, polio, hepatitis B, human papillomavirus, and respiratory syncytial virus, demonstrating platform versatility across diverse antigen types including live attenuated viruses, inactivated whole virions, recombinant proteins, and virus-like particles[48,49,50]. Bacterial vaccines targeting tetanus, diphtheria, and pertussis delivered via microneedles generate protective antibody responses with improved stability profiles compared to liquid formulations[51].

4.2. Pandemic Preparedness and Mass Immunization

The COVID-19 pandemic highlighted critical vulnerabilities in global vaccination infrastructure, including cold-chain limitations, healthcare worker shortages, and vaccine hesitancy partly attributed to injection fears [52]. Microneedle patches address these challenges through thermostable formulations eliminating cold-chain requirements, self-administration potential reducing healthcare system burden, and painless delivery improving patient acceptance [53, 54].

Clinical trials of SARS-CoV-2 spike protein vaccines delivered via dissolving microneedles demonstrate robust neutralizing antibody responses and cellular immunity comparable to approved intramuscular vaccines [55]. Rapid manufacturing scalability through established pharmaceutical processing technologies and simplified distribution logistics position microneedle patches as strategic tools for pandemic response and routine immunization programs in resource-limited settings [56].

4.3. Pediatric and Geriatric Vaccination Strategies

Needle-phobia represents a significant barrier to pediatric vaccination compliance, with studies indicating that pain-free microneedle administration substantially reduces vaccination anxiety and improves acceptance among children and caregivers [57]. Microneedle patch geometry can be optimized for pediatric skin thickness and mechanical properties, ensuring reliable antigen delivery without age-specific dosing concerns [58].

Elderly populations, characterized by immunosenescence and reduced vaccine responsiveness, may particularly benefit from intradermal microneedle delivery due to enhanced dendritic cell activation and improved antibody production relative to intramuscular routes [59]. Clinical studies in geriatric cohorts demonstrate superior seroconversion rates for influenza microneedle vaccines compared to standard-dose intramuscular formulations [60].

5. Challenges and Future Perspectives

5.1. Manufacturing, Stability, and Dose Uniformity

Large-scale microneedle manufacturing presents technical challenges including reproducible needle geometry, uniform antigen distribution, consistent mechanical properties, and high-throughput production capabilities[61]. Micromolding techniques scale effectively to industrial production volumes but require stringent process controls to maintain batch-to-batch consistency in needle dimensions, antigen content, and dissolution kinetics [62].

Dose uniformity across individual needles within arrays and between different patches remains a critical quality attribute requiring analytical validation. Techniques including fluorescence microscopy, Raman spectroscopy, and immunoassays assess antigen spatial distribution and quantitative content [63]. Stability studies under accelerated and real-time conditions establish shelf-life specifications, with optimized formulations demonstrating antigen potency retention exceeding 24 months at ambient temperatures[64].

5.2. Regulatory and Large-Scale Deployment Challenges

Regulatory pathways for microneedle vaccines remain incompletely defined, requiring establishment of quality standards, manufacturing specifications, bioequivalence criteria, and clinical endpoints [65]. Classification as combination products (drug-device) necessitates comprehensive evaluation of both pharmaceutical and device components, including materials biocompatibility, mechanical performance, and user interface validation [66].

Global deployment strategies must address packaging design for tropical climates, simplified instructions for self-administration, waste disposal considerations for dissolvable components, and integration into existing immunization programs [67]. Economic analyses indicate that despite higher per-unit manufacturing costs, microneedle vaccines offer system-level cost savings through cold-chain elimination, reduced medical waste, and decreased healthcare workforce requirements [68].

5.3. Future Innovations in Microneedle Vaccine Platforms

Next-generation developments focus on multi-antigen microneedle patches enabling combination vaccines within single patches, programmed sequential release profiles mimicking prime-boost schedules, and integration of immunological adjuvants for enhanced responses[69]. Smart microneedle systems incorporating biosensors for real-time monitoring of antigen delivery, pH-responsive polymers triggering release at specific skin depths, and temperature-indicating labels verifying proper storage conditions represent emerging innovations[70].

Personalized vaccination approaches utilizing rapidly manufactured microneedles loaded with patient-specific antigens for cancer immunotherapy or neoantigen vaccines exemplify translational opportunities beyond infectious disease prevention[71]. Manufacturing advances including 3D printing, laser ablation, and continuous flow processing promise to reduce production costs and accelerate clinical translation[72].

6. Conclusion

Transdermal microneedle patches represent a transformative vaccination technology addressing critical limitations of conventional needle-syringe immunization through painless administration, thermostability, self-administration potential, and elimination of sharps waste. Diverse microneedle architectures including dissolving, coated, hollow, and hybrid systems offer versatile platforms for delivering viral, bacterial, and subunit vaccines with immunological outcomes comparable or superior to intramuscular routes. The mechanistic advantages of intradermal antigen delivery to skin-resident dendritic cell populations, combined with controlled release formulations and dose-sparing effects, position microneedle vaccines as particularly valuable for pandemic preparedness, mass immunization campaigns, and populations with special needs. While manufacturing scalability, regulatory frameworks, and stability optimization require continued refinement, multiple clinical trials advancing toward regulatory approval signal imminent clinical implementation. Future innovations integrating adjuvant technologies, multi-antigen formulations, and personalized medicine approaches promise to establish microneedle patches as mainstream vaccination platforms, fundamentally transforming global immunization strategies and improving healthcare accessibility worldwide.



Fig 1: Types and structural designs of transdermal microneedle patches



Fig 2: Mechanism of skin penetration and antigen delivery via microneedles



Fig 3: Real-life experimental photograph of a dissolvable microneedle vaccine patch (influenza, Phase I trial by Georgia Tech/Emory), showing a flexible, bandage-like patch with a translucent backing and central array of hundreds of tiny (~650 μm) dissolving microneedles held between fingers, designed for painless, self-administered skin delivery without needles or refrigeration.

Table 1: Classification of microneedle systems used for vaccine delivery

Microneedle Type	Structural Characteristics	Antigen Loading Method	Dissolution/Delivery Time	Clinical Status
Solid	Non-biodegradable silicon, metal, or polymer projections	Applied after microchannel creation	Instant microchannels, separate application	Limited clinical use
Coated	Metal or silicon base with surface antigen coating	Dip-coating, spray-coating, electrospray	1-5 minutes coating dissolution	Clinical trials completed
Dissolving	Entirely water-soluble/biodegradable polymer matrix	Antigen encapsulation during fabrication	5-30 minutes complete dissolution	Phase III trials ongoing
Biodegradable	Slowly degrading polymers (PLA, PLGA)	Encapsulation in polymer matrix	Hours to weeks sustained release	Preclinical/early clinical
Hollow	Miniaturized needles with central bore	Liquid vaccine infusion	Seconds to minutes infusion	Early clinical development
Hybrid	Dissolving tips + non-dissolving backing	Tip encapsulation, backing support	Variable based on tip composition	Preclinical optimization

Table 2: Materials and fabrication techniques for microneedle patches

Material Category	Specific Materials	Fabrication Method	Advantages	Limitations
Water-soluble polymers	PVP, PVA, CMC, maltose, trehalose	Micromolding, casting	Rapid dissolution, biocompatible, GRAS status	Limited mechanical strength, moisture sensitivity
Biodegradable polymers	PLA, PLGA, PCL, silk fibroin	Micromolding, hot embossing	Sustained release, tunable degradation	Slower dissolution, organic solvents required
Natural biopolymers	Hyaluronic acid, chitosan, gelatin, dextran	Micromolding, freeze-drying	High biocompatibility, natural origin	Variable purity, batch inconsistency
Metals	Stainless steel, titanium	Laser cutting, electroplating, etching	High mechanical strength, reusable	Non-biodegradable, coating required
Silicon	Monocrystalline silicon	Photolithography, deep reactive ion etching	Precise geometry, sharp tips	Brittle, expensive, non-biodegradable
Ceramics	Alumina, calcium phosphate	Sintering, 3D printing	Biocompatible, rigid	Brittle fracture risk
Hybrid systems	Polymer-metal, polymer-ceramic composites	Multi-step molding, layer-by-layer	Combined advantages, multi-functionality	Complex fabrication, higher cost

Table 3: Vaccine types delivered using microneedle patches and immunological outcomes

Vaccine Category	Specific Vaccines	Antigen Type	Microneedle System	Immunological Outcomes	Clinical Trial Phase
Influenza	Seasonal influenza, H1N1, H5N1	Inactivated virus, recombinant HA	Dissolving PVP/PVA patches	Non-inferior antibody titers, improved thermostability	Phase III
COVID-19	SARS-CoV-2 spike protein	Recombinant protein, mRNA	Dissolving CMC patches, coated arrays	Neutralizing antibodies, cellular immunity	Phase I/II
Measles	Measles-mumps-rubella	Live attenuated virus	Dissolving maltose patches	Seroconversion >90%, dose-sparing	Phase I
Polio	Inactivated poliovirus	Killed virus	Dissolving hyaluronic acid	Protective antibody responses	Preclinical
Hepatitis B	HBsAg	Recombinant protein	Coated metal microneedles	Enhanced seroprotection vs IM	Phase I
HPV	Human papillomavirus L1 VLP	Virus-like particles	Dissolving silk fibroin	Comparable neutralizing titers	Preclinical
Tetanus-diphtheria	Toxoid antigens	Inactivated toxins	Dissolving PVP patches	Protective antibody levels maintained	Phase I
Rabies	Inactivated rabies virus	Killed virus	Coated microneedles	Rapid antibody response, dose reduction	Preclinical

Table 4: Advantages, limitations, and clinical challenges of microneedle-based vaccine delivery

Aspect	Advantages	Limitations	Clinical Challenges	Proposed Solutions
Patient acceptance	Painless, minimal invasiveness, reduced needle phobia	Initial unfamiliarity, self-administration training	User compliance verification, application technique variation	Clear instructions, feedback indicators, training programs
Immunological response	Enhanced dendritic cell targeting, dose-sparing effect, improved cellular immunity	Inter-individual skin variability, insertion depth control	Standardized immune response assessment, correlates of protection	Biomarker development, controlled insertion devices
Stability	Room temperature storage, reduced cold-chain dependence	Moisture sensitivity, antigen stability during fabrication	Long-term stability validation, tropical climate storage	Desiccant packaging, stabilizing excipients, hermetic sealing
Manufacturing	Scalable micromolding, established pharmaceutical processes	Dose uniformity challenges, quality control complexity	Batch consistency, regulatory analytical methods	Process analytical technology, automated inspection
Cost-effectiveness	Eliminated cold-chain, reduced medical waste, self-administration	Higher per-unit manufacturing costs	Economic modeling, reimbursement structures	Volume production, simplified designs, policy frameworks
Regulatory approval	Established vaccine regulatory pathways	Combination product classification, novel delivery route	Bioequivalence criteria, clinical endpoint definition	Regulatory guidance documents, international harmonization
Global deployment	Simplified logistics, sharps waste elimination	Packaging optimization, cultural acceptance	Distribution infrastructure, waste management education	Stakeholder engagement, pilot programs, community outreach

7. References

1. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369-393.
2. Taddio A, Ipp M, Thivakaran S, *et al*. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 2012;30(32):4807-4812.
3. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547-1568.
4. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J Control Release. 2007;117(2):227-237.
5. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev. 2010;234(1):120-141.
6. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197-3208.
7. Glenn GM, Kenney RT. Mass vaccination: solutions in the skin. Curr Top Microbiol Immunol. 2006;304:247-268.
8. Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998;87(8):922-925.
9. Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human volunteers. Clin J Pain. 2008;24(7):585-594.
10. Nguyen TT, Park JH. Human studies with microneedles for evaluation of their efficacy and safety. Expert Opin Drug Deliv. 2018;15(3):235-245.
11. Kommareddy S, Baudner BC, Bonificio A, *et al*. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J Pharm Sci. 2012;101(3):1021-1027.
12. Kim NW, Lee MS, Kim KR, *et al*. Polypeptide microneedle patches for vaccine delivery. J Control Release. 2014;196:290-297.
13. Mistilis MJ, Joyce JC, Esser ES, *et al*. Long-term stability of influenza vaccine in a dissolving microneedle patch. Drug Deliv Transl Res. 2017;7(2):195-205.
14. Sullivan SP, Murthy N, Prausnitz MR. Minimally

invasive protein delivery with rapidly dissolving polymer microneedles. Adv Mater. 2008;20(5):933-938.
15. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. Biomaterials. 2008;29(13):2113-2124.
16. Donnelly RF, Singh TR, Garland MJ, *et al*. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. Adv Funct Mater. 2012;22(23):4879-4890.
17. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res. 2009;26(2):395-403.
18. Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release. 2005;104(1):51-66.
19. DeMuth PC, Li AV, Abbink P, *et al*. Vaccine delivery with microneedle skin patches in nonhuman primates. Nat Biotechnol. 2013;31(12):1082-1085.
20. Raphael AP, Crichton ML, Falconer RJ, *et al*. Formulations for microprojection/microneedle vaccine delivery: structure, strength and release profiles. J Control Release. 2016;225:40-52.
21. Chen X, Prow TW, Crichton ML, *et al*. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release. 2009;139(3):212-220.
22. Davis SP, Martanto W, Allen MG, Prausnitz MR. Hollow metal microneedles for insulin delivery to diabetic rats. IEEE Trans Biomed Eng. 2005;52(5):909-915.
23. Martanto W, Davis SP, Holiday NR, *et al*. Transdermal delivery of insulin using microneedles *in vivo*. Pharm Res. 2004;21(6):947-952.
24. Lahiji SF, Dangol M, Jung H. A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery. Sci Rep. 2015;5:7914.
25. Chu LY, Prausnitz MR. Separable arrowhead microneedles. J Control Release. 2011;149(3):242-249.
26. Gupta J, Felner EI, Prausnitz MR. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther. 2009;11(6):329-337.
27. Loizidou EZ, Inoue NT, Ashton-Barnett J, Barrow DA, Allender CJ. Evaluation of geometrical effects of microneedles on skin penetration by CT scan and finite element analysis. Eur J Pharm Biopharm. 2016;107:1-6.
28. Haq MI, Smith E, John DN, *et al*. Clinical administration of microneedles: skin puncture, pain and sensation. Biomed Microdevices. 2009;11(1):35-47.
29. Olatunji O, Das DB, Garland MJ, Belaid L, Donnelly RF. Influence of array interspacing on the force required for successful microneedle skin penetration: theoretical and practical approaches. J Pharm Sci. 2013;102(4):1209-1221.
30. Bal SM, Caussin J, Pavel S, Bouwstra JA. *In vivo* assessment of safety of microneedle arrays in human skin. Eur J Pharm Sci. 2008;35(3):193-202.
31. Kim S, Yang H, Eum J, *et al*. Implantable powder-carrying microneedles for transdermal delivery of high-dose insulin with enhanced activity. Biomaterials. 2020;232:119733.
32. Zhu W, Pewin W, Wang C, *et al*. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines. J Control Release. 2017;261:1-9.
33. Peyraud N, Zehrung D, Jarrahian C, Frivold C, Orubu T, Giersing B. Potential use of microarray patches for vaccine delivery in low- and middle-income countries. Vaccine. 2019;37(32):4427-4434.
34. Chen MC, Ling MH, Kusuma SJ. Poly-γ-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin. Acta Biomater. 2015;24:106-116.
35. Mistilis MJ, Bommarius AS, Prausnitz MR. Development of a thermostable microneedle patch for influenza vaccination. J Pharm Sci. 2015;104(2):740-749.
36. Demuth PC, Min Y, Huang B, *et al*. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater. 2013;12(4):367-376.
37. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004;4(3):211-222.
38. Romani N, Brunner PM, Stingl G. Changing views of the role of Langerhans cells. J Invest Dermatol. 2012;132(3 Pt 2):872-881.
39. Hickling JK, Jones KR, Friede M, Zehrung D, Chen D, Kristensen D. Intradermal delivery of vaccines: potential benefits and current challenges. Bull World Health Organ. 2011;89(3):221-226.
40. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines. 2008;7(8):1201-1214.
41. Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, *et al*. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One. 2009;4(3):e4773.
42. Kim YC, Jarrahian C, Zehrung D, Mitragotri S, Prausnitz MR. Delivery systems for intradermal vaccination. Curr Top Microbiol Immunol. 2012;351:77-112.
43. Fernando GJ, Chen X, Prow TW, *et al*. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One. 2010;5(4):e10266.
44. Rouphael NG, Paine M, Mosley R, *et al*. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial. Lancet. 2017;390(10095):649-658.
45. Hirobe S, Azukizawa H, Hanafusa T, *et al*. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 2015;57:50-58.
46. Kim E, Erdos G, Huang S, *et al*. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine. 2020;55:102743.
47. Joyce JC, Carroll TD, Collins ML, *et al*. A microneedle patch for measles and rubella vaccination is immunogenic in infant rhesus macaques. J Infect Dis. 2018;218(1):124-132.
48. Edens C, Collins ML, Goodson JL, Rota PA, Prausnitz MR. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. 2015;33(37):4712-4718.

49. Poirier D, Renaud F, Dewar V, *et al*. Hepatitis B surface antigen incorporated in dissolvable microneedle array patch is antigenic and thermostable. Biomaterials. 2017;145:256-265.
50. Littauer EQ, Mills LK, Brock N, Esser ES, Romanyuk A, Pulit-Penaloza JA. Stable incorporation of GM-CSF into dissolvable microneedle patches. Drug Deliv Transl Res. 2018;8(6):1691-1702.
51. Joyce J, Erdo G, Sizer T, *et al*. Tetanus toxoid and diphtheria toxoid vaccine delivered as a microneedle patch is immunogenic in rats and guinea pigs. Vaccine. 2022;40(47):6752-6761.
52. Caudill C, Perry JL, Iliadis K, *et al*. Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity. Proc Natl Acad Sci USA. 2021;118(39):e2102595118.
53. Li W, Terry RN, Tang J, *et al*. Rapidly separable microneedle patch for the sustained release of a contraceptive. Nat Biomed Eng. 2019;3(3):220-229.
54. Vrdoljak A, McGrath MG, Carey JB, *et al*. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release. 2012;159(1):34-42.
55. McAllister DV, Wang PM, Davis SP, *et al*. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc Natl Acad Sci USA. 2003;100(24):13755-13760.
56. Arya J, Henry S, Kalluri H, *et al*. Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects. Biomaterials. 2017;128:1-7.
57. Norman JJ, Arya JM, McClain MA, *et al*. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine. 2014;32(16):1856-1862.
58. Siddharthan V, Kim YC, Liu S, Prausnitz MR. Coated microneedles for the transdermal delivery of live virus vaccines. Biomaterials. 2009;30(19):3275-3282.
59. Holland D, Booy R, De Looze F, *et al*. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198(5):650-658.
60. Fernando GJ, Hickling J, Jayashi Flores CM, *et al*. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). Vaccine. 2018;36(26):3779-3788.
61. Mistilis MJ, Bommarius AS, Prausnitz MR. Development of a thermostable microneedle patch for influenza vaccination. J Pharm Sci. 2015;104(2):740-749.
62. Prausnitz MR. Engineering microneedle patches for vaccination and drug delivery to skin. Annu Rev Chem Biomol Eng. 2017;8:177-200.
63. Moniz T, Costa Lima SA, Reis S. Human skin models: from healthy to disease-mimetic systems; characteristics and applications. Br J Pharmacol. 2020;177(24):5504-5520.
64. Kim YC, Grossniklaus HE, Edelhauser HF, Prausnitz MR. Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization. Invest Ophthalmol Vis Sci. 2014;55(11):7376-7386.
65. Hirschberg HJ, van Kuijk S, Loch JP, *et al*. A combined approach of vesicle formulations and microneedle arrays for transcutaneous immunization against hepatitis B virus. Eur J Pharm Sci. 2012;46(1-2):1-7.
66. Marshall S, Sahm LJ, Moore AC. The success of microneedle-mediated vaccine delivery into skin. Hum Vaccin Immunother. 2016;12(11):2975-2983.
67. Arya JM, Dewitt K, Scott-Garrard M, Chiang YW, Prausnitz MR. Rabies vaccination in dogs using a dissolving microneedle patch. J Control Release. 2016;239:19-26.
68. Rodgers AM, Cordeiro AS, Donnelly RF. Technology update: dissolvable microneedle patches for vaccine delivery. Med Devices (Auckl). 2019;12:379-398.
69. Caffrey CR, Rohwer A, Prausnitz MR, *et al*. How far away are dissolvable microarray patches for HIV/AIDS vaccine delivery? Expert Opin Drug Deliv. 2015;12(4):639-657.
70. Kolluru C, Gomaa Y, Prausnitz MR. Development of a thermostable microneedle patch for polio vaccination. Drug Deliv Transl Res. 2019;9(1):192-203.
71. Kochba E, Levin Y, Raz I, Cahn A. Improved insulin pharmacokinetics using a novel microneedle device for intradermal delivery in patients with type 2 diabetes. Diabetes Technol Ther. 2016;18(9):525-531.
72. Mukherjee P, Nathamgari SS, Kessler JA, Espinosa HD. Combined numerical and experimental investigation of localized electroporation-based cell transfection and sampling. ACS Nano. 2018;12(12):12118-12128.